argent said:
Can you post these studies bro if it is all possible?
Give a man a fish and he will eat for a day. Teach a man to fish and he will eat for a lifetime.
Go to the National Center for Biotechnology Information and study to your heart's content. It's pretty self-explanatory as to how to find what you want.
http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi
MaxRep
P.S. for those of you who have a phobia of reading scientific studies, here's one abstract on a study just published, regarding aromasin. Keep in mind, you can not necessarily directly take as gospel information from one study. You need to read multiple studies and start seeing what's consistent and what's not consistent among them.
___________________________________________________________________
J Clin Endocrinol Metab. 2003 Dec;88(12):5951-6.
Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.
Mauras N, Lima J, Patel D, Rini A, Di Salle E, Kwok A, Lippe B.
Nemours Children's Clinic and Research Programs (N.M., J.L., A.R.), Jacksonville, Florida 32207.
Suppression of estrogen, via estrogen receptor or aromatase blockade, is being investigated in the treatment of different conditions. Exemestane (Aromasin) is a potent and selective irreversible aromatase inhibitor. To characterize its suppression of estrogen and its pharmacokinetic (PK) properties in males, healthy eugonadal subjects (14-26 yr of age) were recruited. In a cross-over study, 12 were randomly assigned to 25 and 50 mg exemestane daily, orally, for 10 d with a 14-d washout period. Blood was withdrawn before and 24 h after the last dose of each treatment period. A PK study was performed (n = 10) using a 25-mg dose. Exemestane suppressed plasma estradiol comparably with either dose [25 mg, 38% (P </= 0.002); 50 mg, 32% (P </= 0.008)], with a reciprocal increase in testosterone concentrations (60% and 56%; P </= 0.003 for both).
Plasma lipids and IGF-I concentrations were unaffected by treatment. The PK properties of the 25-mg dose showed the highest exemestane concentrations 1 h after administration, indicating rapid absorption. The terminal half-life was 8.9 h. Maximal estradiol suppression of 62 +/- 14% was observed at 12 h. The drug was well tolerated. In conclusion, exemestane is a potent aromatase inhibitor in men and an alternative to the choice of available inhibitors. Long-term efficacy and safety will need further study.
